The aim of this work is the determination of synthesis conditions, composition, structure, antitumor properties of copper(II), nickel(II) and cobalt(III) coordination compounds with 2-[(pyridin-2-ylmethylidene)amino]butan-1-ol (HL1), 2-{[1-(pyridin-2-yl)ethylidene]amino}butan-1-ol (HL2) and 2-{[phenyl(pyridin-2yl)methylidene]amino}butan-1-ol (HL3). The synthesis of coordination compounds was performed in ethanolic solutions using template method. 2-Aminobutanole reacts with 2-formylpyridine (HL1), 2-acetylpyridine (HL2) and 2-benzoylpyridine (HL3) in presence of copper(II), nickel(II) and cobalt(II) chlorides, bromides, nitrates, perchlorates and acetates taken in molar ratio 2:2:1 or 1:1:1. The composition of these compounds was determined using elemental analysis: Cu(HL1-3)X2, Cu(L1-3)X, Ni(L1-3)2 and Co(L1-3)2X (X = Cl-, Br-, NO3-, ClO4-). The magnetochemical research showed that the synthesized coordination compounds of copper are polynuclear, coordination compounds of nickel and cobalt have octahedral structure. Azomethines HL1-3 behave as neutral or mono-deprotonated tridentate ligands with N,N,O set of donor atoms. The antiproliferative activity of the synthesized coordination compounds was studied on cancer cells Hep G-2 and BxPC-3. It was determined that these compounds inhibit the proliferation of these tumor cells in the range of concentration 100-0.1 μmol/L. The inhibitory concentrations IC50 towards the Hep G-2 cells are in the range of 26.7-99.6 μmol/L. Towards the BxPC-3 cells IC50 values are in the range of 11.7-40.7 μmol/L. It was shown that the nature of the central atom and substituent R in the corresponding azomethine and also the acid residue have an influence on the antitumor activity of these complexes. For the homotypic complexes the activity diminishes in the following way: Cu > Co ≈ Ni; HL1 > HL2 ≈ HL3; Cl- ≈ Br NO3- ≈ ClO4-. Synthesized compounds manifest better activity towards BxPC-3 cells. The determinated properties of the synthesized substances are of interest for medical practice for enhancement of the arsenal of antitumor preparations.